Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Updated COPD-X guide reflects stronger evidence for triple therapy

LRTI rates fall by 30% in Indigenous infants but still a long way to go

Make telehealth items a permanent feature for specialists: AMA

No need to ‘reinvent the wheel’ on post-COVID rehab programs, say clinicians

CPAP helps with sleep but not dysfunctional breathing

COPD

PBS restrictions on COPD meds a nudge towards best practice

By Mardi Chapman

19 Oct 2017

The PBAC has recommended increasing the PBS restriction level to Authority Required (Streamlined) for ICS/LABA inhalers in COPD and removing the current restrictions to stabilise patients on individual monotherapy inhalers before commencing a LAMA/LABA combination. The recommendations follow the yet to be published Post-market Review of Chronic Obstructive Pulmonary Disease (COPD) Medicines, reinforce COPD-X guidelines and ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories